Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Metrics to compare | RVX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRVXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.9x | −4.0x | −0.7x | |
PEG Ratio | 9.69 | −0.09 | 0.00 | |
Price/Book | −0.2x | 1.8x | 2.6x | |
Price / LTM Sales | - | 6.0x | 3.4x | |
Upside (Analyst Target) | - | 136.4% | 35.7% | |
Fair Value Upside | Unlock | −6.7% | 4.1% | Unlock |